← Eichor
Study identifier: NCT04207814 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Determinants of Repeated Spontaneous Miscarriages and Unexplained Fetal Deaths

Condition: Repeated Spontaneous Miscarriages · Fetal Deaths in Utero  ·  Sponsor: University Hospital, Brest

PhaseNA
Planned participants200
Who can joinAll sexes, 18 Years to 40 Years
Healthy volunteersNo

About this study

The DEFI-1 study recruited 625 women witnesses and 299 of their spouses. With regard to case couples, 271 cases were recruited from the spontaneous repeated miscarriages (SRM) subgroup (≥3 spontaneous miscarriage (SM) from trimester 1 of pregnancy) and 93 from the unexplained fetal death in utero (FDIU) subgroup from trimesters 2 and 3 of pregnancy. The main objective of the DEFI 2 study is to increase the number of case-pairs in these 2 particular subgroups to replicate the results of the genetic determinants highlighted from cases and controls with extreme phenotypes and obtain a sufficient number of women with FDIUs to identify specific determinants.

This description comes directly from the study's public registry record.

Talk to the study team

Elisabeth Pasquier, MD  ·  0298145013  ·  elisabeth.pasquier@chu-brest.fr

Always discuss trial participation with your own doctor first.

Locations (1)

BRESTBrest, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04207814